Skip to main content

Table 1 Most commonly reported adverse events in PATRO Children (incidence > 7.0) and PATRO Adults (incidence > 10.0)

From: Ten years with biosimilar rhGH in clinical practice in Sweden – experience from the prospective PATRO children and adult studies

MedDRA dictionary preferred term

Maximum intensity

Total patients

n (%)

Incidencea

Mild

n (%)

Moderate

n (%)

Severe

n (%)

Missing

n (%)

PATRO Children

 Nasopharyngitis

13 (9.6)

3 (2.2)

0 (0.0)

0 (0.0)

16 (11.8)

31.70

 Ear infection

1 (0.7)

4 (2.9)

0 (0.0)

0 (0.0)

5 (3.7)

9.91

 Varicella

2 (1.5)

2 (1.5)

0 (0.0)

1 (0.7)

5 (3.7)

9.91

 Viral infection

4 (2.9)

1 (0.7)

0 (0.0)

0 (0.0)

5 (3.7)

9.91

 Headache

1 (0.7)

3 (2.2)

0 (0.0)

0 (0.0)

4 (2.9)

7.93

 Pneumonia

1 (0.7)

3 (2.2)

0 (0.0)

0 (0.0)

4 (2.9)

7.93

 Vomiting

3 (2.2)

1 (0.7)

0 (0.0)

0 (0.0)

4 (2.9)

7.93

PATRO Adults

 Fatigue

20 (6.8)

6 (2.0)

0 (0.0)

0 (0.0)

26 (8.9)

23.82

 Arthralgia

13 (4.4)

3 (1.0)

0 (0.0)

1 (0.3)

17 (5.8)

15.58

 Headache

9 (3.1)

4 (1.4)

0 (0.0)

0 (0.0)

13 (4.4)

11.91

 Nasopharyngitis

11 (3.8)

2 (0.7)

0 (0.0)

0 (0.0)

13 (4.4)

11.91

 Dizziness

9 (3.1)

1 (0.3)

2 (0.7)

0 (0.0)

12 (4.1)

11.0

 Neoplasm progression

1 (0.3)

4 (1.4)

7 (2.4)

0 (0.0)

12 (4.1)

11.0

 Osteopenia

12 (4.1)

0 (0.0)

0 (0.0)

0 (0.0)

12 (4.1)

11.0

 Edema peripheral

7 (2.4)

3 (1.0)

1 (0.3)

0 (0.0)

11 (3.8)

10.08

  1. aIncidence is defined as the number of patients with respective AE per 1000 patient-years; PATRO Children patient-years = 504.7, PATRO Adults patient-years = 1091.3
  2. AE Adverse event, PATRO Patients TReated with Omnitrope®